Subscribe To
Kiora pharmaceuticals announces participation at 2022 bio ceo & investor conference
Salt Lake City, Utah--(Newsfile Corp. - February 8, 2022) - Kiora pharmaceuticals, Inc. (NASDAQ: KPRX),...
February 8, 2022, 6:45 am
Kiora pharmaceuticals announces participation at 2022 bio ceo & investor conference
Salt Lake City, Utah--(Newsfile Corp. - February 8, 2022) - Kiora pharmaceuticals, Inc. (NASDAQ: KPRX),...
February 8, 2022, 6:45 am
Caribou biosciences to present at the svb leerink 11th annual global healthcare conference
BERKELEY, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing bio...
February 7, 2022, 4:05 pm
Caribou biosciences to present at the svb leerink 11th annual global healthcare conference
BERKELEY, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing bio...
February 7, 2022, 4:05 pm
Caribou biosciences to present at the svb leerink 11th annual global healthcare conference
BERKELEY, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing bio...
February 7, 2022, 4:05 pm
Teva, texas enter $225m opioid settlement agreement
Teva pharmaceutical Industries Ltd TEVA has reached a settlement worth $225 million to resolve clai...
February 7, 2022, 2:16 pm
Teva, texas enter $225m opioid settlement agreement
Teva pharmaceutical Industries Ltd TEVA has reached a settlement worth $225 million to resolve clai...
February 7, 2022, 2:16 pm
Teva, texas enter $225m opioid settlement agreement
Teva pharmaceutical Industries Ltd TEVA has reached a settlement worth $225 million to resolve clai...
February 7, 2022, 2:16 pm
Updated guidance and royalty pharma financing demolish short thesis for biocryst pharmaceuticals
Royalty Pharma and OMERS Capital Markets (OMERS) recently committed $350 million in non-dilutive funding for BioCryst. BioCryst generated $120 million...
February 7, 2022, 11:56 am
Updated guidance and royalty pharma financing demolish short thesis for biocryst pharmaceuticals
Royalty Pharma and OMERS Capital Markets (OMERS) recently committed $350 million in non-dilutive funding for BioCryst. BioCryst generated $120 million...
February 7, 2022, 11:56 am
Updated guidance and royalty pharma financing demolish short thesis for biocryst pharmaceuticals
Royalty Pharma and OMERS Capital Markets (OMERS) recently committed $350 million in non-dilutive funding for BioCryst. BioCryst generated $120 million...
February 7, 2022, 11:56 am
Here's why vertex pharmaceuticals (vrtx) is a strong momentum stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage....
February 7, 2022, 11:34 am
Here's why vertex pharmaceuticals (vrtx) is a strong momentum stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage....
February 7, 2022, 11:34 am
Here's why vertex pharmaceuticals (vrtx) is a strong momentum stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage....
February 7, 2022, 11:34 am
Catalyst pharma expects fy22 revenue beat consensus on continued recovery in macroeconomic, healthcare activity
Catalyst pharmaceuticals Inc CPRX anticipates Q4 FY21 sales of approximately $38 million (consensus ...
February 7, 2022, 10:27 am
Catalyst pharma expects fy22 revenue beat consensus on continued recovery in macroeconomic, healthcare activity
Catalyst pharmaceuticals Inc CPRX anticipates Q4 FY21 sales of approximately $38 million (consensus ...
February 7, 2022, 10:27 am
Catalyst pharma expects fy22 revenue beat consensus on continued recovery in macroeconomic, healthcare activity
Catalyst pharmaceuticals Inc CPRX anticipates Q4 FY21 sales of approximately $38 million (consensus ...
February 7, 2022, 10:27 am
Aeterna zentaris to present at the 2022 bio ceo & investor conference
CHARLESTON, S.C., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty...
February 7, 2022, 8:05 am
Aeterna zentaris to present at the 2022 bio ceo & investor conference
CHARLESTON, S.C., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty...
February 7, 2022, 8:05 am
Aeterna zentaris to present at the 2022 bio ceo & investor conference
CHARLESTON, S.C., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty...
February 7, 2022, 8:05 am